Other Clinical Trial - Glasdegib for Chronic Graft-Versus-Host Disease

Status Terminated

Clinical Trial Summary

This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.

Clinical Trial Description

OUTLINE: This is a phase I/II study. Patients receive glasdegib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity. ;

Study Design

Related Conditions & MeSH terms

Bronchiolitis Obliterans Syndrome
Chronic Graft Versus Host Disease
Fasciitis
Graft vs Host Disease

Clinical Trial Details

NCT number	NCT04111497
Study type	Interventional
Source	Fred Hutchinson Cancer Center
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	December 3, 2019
Completion date	August 23, 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Terminated	`NCT02337517` - Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease	Phase 2
Terminated	`NCT02461134` - Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD	Phase 2
Recruiting	`NCT03839069` - Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis	N/A
Active, not recruiting	`NCT00637689` - Improving Outcomes Assessment in Chronic GVHD
Active, not recruiting	`NCT01937468` - Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease	Phase 1
Completed	`NCT01380535` - Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)	Early Phase 1
Completed	`NCT01810718` - Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD	Phase 1
Terminated	`NCT01964625` - Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)	N/A
Active, not recruiting	`NCT03790332` - Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)	Phase 1/Phase 2
Completed	`NCT01680965` - Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease	Phase 1/Phase 2
Completed	`NCT02491359` - Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease	Phase 2
Terminated	`NCT02701634` - Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)	Phase 2
Recruiting	`NCT06247150` - Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)	N/A
Active, not recruiting	`NCT04212416` - Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease	Phase 1
Completed	`NCT02959944` - Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)	Phase 3
Completed	`NCT01954979` - Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)	Phase 1
Active, not recruiting	`NCT04640025` - A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib	Phase 2
Completed	`NCT03483675` - Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease	Phase 2
Recruiting	`NCT04431479` - Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study